Impact of Time to Treatment on Mortality After Prehospital Fibrinolysis or Primary Angioplasty: Data From the CAPTIM Randomized Clinical Trial
暂无分享,去创建一个
P. Touboul | P. Steg | E. Bonnefoy | F. Lapostolle | A. Leizorovicz | S. Chabaud | P. Cristofini | P. Dubien
[1] G. Levine,et al. Thrombolysis in acute myocardial infarction complicated by cardiogenic shock , 2005, Journal of Thrombosis and Thrombolysis.
[2] R. Manfredini,et al. Impact of time to treatment on mortality after prehospital fibrinolysis or primary angioplasty. , 2004, Circulation.
[3] Klaus Rasmussen,et al. A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction. , 2003, The New England journal of medicine.
[4] J. Henriques,et al. Outcome of primary angioplasty for acute myocardial infarction during routine duty hours versus during off-hours. , 2003, Journal of the American College of Cardiology.
[5] P. Serruys,et al. Fibrinolytic therapy: is it a treatment of the past? , 2003, Circulation.
[6] J. Boura,et al. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction : a quantitative review of 23 randomised trials , 2022 .
[7] M. Aschermann,et al. Long distance transport for primary angioplasty vs immediate thrombolysis in acute myocardial infarction. Final results of the randomized national multicentre trial--PRAGUE-2. , 2003, European heart journal.
[8] F. Zijlstra. Angioplasty vs thrombolysis for acute myocardial infarction: a quantitative overview of the effects of interhospital transportation. , 2003, European heart journal.
[9] P. Touboul,et al. Primary angioplasty versus prehospital fibrinolysis in acute myocardial infarction: a randomised study , 2002, The Lancet.
[10] J. Reiner,et al. How long is too long? Association of time delay to successful reperfusion and ventricular function outcome in acute myocardial infarction: the case for thrombolytic therapy before planned angioplasty for acute myocardial infarction. , 2002, American heart journal.
[11] R. Gibbons,et al. Clinical characteristics and outcome of patients with early (<2 h), intermediate (2-4 h) and late (>4 h) presentation treated by primary coronary angioplasty or thrombolytic therapy for acute myocardial infarction. , 2002, European heart journal.
[12] William W O'Neill,et al. A randomized trial of transfer for primary angioplasty versus on-site thrombolysis in patients with high-risk myocardial infarction: the Air Primary Angioplasty in Myocardial Infarction study. , 2002, Journal of the American College of Cardiology.
[14] R. Gibbons,et al. Clinical characteristics and outcome of patients with early ( 4 h) presentation treated by primary coronary angioplasty or thrombolytic therapy for acute myocardial infarction. , 2002 .
[15] Á. Avezum,et al. Practice variation and missed opportunities for reperfusion in ST-segment-elevation myocardial infarction: findings from the Global Registry of Acute Coronary Events (GRACE) , 2002, The Lancet.
[16] E. Antman,et al. Early coronary intervention following pharmacologic therapy for acute myocardial infarction (the combined TIMI 10B-TIMI 14 experience). , 2001, The American journal of cardiology.
[17] C M Gibson,et al. Relationship of symptom-onset-to-balloon time and door-to-balloon time with mortality in patients undergoing angioplasty for acute myocardial infarction. , 2000, JAMA.
[18] L. Morrison,et al. Mortality and prehospital thrombolysis for acute myocardial infarction: A meta-analysis. , 2000, JAMA.
[19] H. Suryapranata,et al. Multicentre randomized trial comparing transport to primary angioplasty vs immediate thrombolysis vs combined strategy for patients with acute myocardial infarction presenting to a community hospital without a catheterization laboratory. The PRAGUE study. , 2000, European heart journal.
[20] S. Greenhouse,et al. A randomized trial comparing primary angioplasty with a strategy of short-acting thrombolysis and immediate planned rescue angioplasty in acute myocardial infarction: the PACT trial , 1999 .
[21] H. White,et al. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock. , 1999, The New England journal of medicine.
[22] R. Califf,et al. Relationship between delay in performing direct coronary angioplasty and early clinical outcome in patients with acute myocardial infarction: results from the global use of strategies to open occluded arteries in Acute Coronary Syndromes (GUSTO-IIb) trial. , 1999, Circulation.
[23] J. Golmard,et al. A matched comparison of the combination of prehospital thrombolysis and standby rescue angioplasty with primary angioplasty. , 1999, The American journal of cardiology.
[24] R. Califf,et al. Frequency and clinical outcome of cardiogenic shock during acute myocardial infarction among patients receiving reteplase or alteplase Results from GUSTO-III , 1999 .
[25] R. Califf,et al. Frequency and clinical outcome of cardiogenic shock during acute myocardial infarction among patients receiving reteplase or alteplase. Results from GUSTO-III. Global Use of Strategies to Open Occluded Coronary Arteries. , 1999, European heart journal.
[26] F. Portaluppi,et al. From a static to a dynamic concept of risk: the circadian epidemiology of cardiovascular events. , 1999, Chronobiology international.
[27] S. Greenhouse,et al. A randomized trial comparing primary angioplasty with a strategy of short-acting thrombolysis and immediate planned rescue angioplasty in acute myocardial infarction: the PACT trial. PACT investigators. Plasminogen-activator Angioplasty Compatibility Trial. , 1999, Journal of the American College of Cardiology.
[28] J. Golmard,et al. Efficacy of streptokinase, but not tissue-type plasminogen activator, in achieving 90-minute patency after thrombolysis for acute myocardial infarction decreases with time to treatment. PERM Study Group. Prospective Evaluation of Reperfusion Markers. , 1998, Journal of the American College of Cardiology.
[29] R. Gibbons,et al. Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review. , 1998, JAMA.
[30] Eric Boersma,et al. Early thrombolytic treatment in acute myocardial infarction: reappraisal of the golden hour , 1996, The Lancet.
[31] P. Kurnik. Circadian variation in the efficacy of tissue-type plasminogen activator. , 1995, Circulation.
[32] C. Fry,et al. Science of urinary incontinence Report of a Meeting of Physicians and Scientists, University College London , 1994, The Lancet.
[33] Fibrinolytic Therapy Trialists' Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients , 1994, The Lancet.
[34] Fibrinolytictherapytrialistsf. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients , 1994 .
[35] Johan Herlitz,et al. Indications for fibrinolytic therapy in suspected acute myocardial infarction : collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients , 1994 .
[36] P. Kudenchuk,et al. Prehospital-initiated vs hospital-initiated thrombolytic therapy. The Myocardial Infarction Triage and Intervention Trial. , 1993, JAMA.
[37] Prehospital thrombolytic therapy in patients with suspected acute myocardial infarction. , 1993, The New England journal of medicine.
[38] J. Boissel,et al. Coronary Reperfusion Rates in Acute Myocardial Infarction Patients After Thrombolytic Treatment with Anistreplase: Correlation with the Delay from Onset of Symptoms to Treatment A Review of 424 Case Records of Patients Admitted to Coronary Reperfusion Studies with Anistreplase , 1992, Journal of cardiovascular pharmacology.
[39] T. Lüscher,et al. Endothelium‐Dependent Regulation of Resistance Arteries: Alterations with Aging and Hypertension , 1992, Journal of cardiovascular pharmacology.
[40] Dwight E. Peake,et al. Thrombolysis in myocardial infarction (TIMI) trial: Phase I. A comparison between intravenous tissue plasminogen activator and intravenous streptokinase , 1988 .
[41] R Roberts,et al. Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. , 1987, Circulation.
[42] Harold T. Dodge,et al. Thrombolysis inMyocardial Infarction (TIMI) Trial, Phase I:acomparison between intravenous tissue plasminogen activator andintravenous streptokinase* , 1987 .
[43] J. Lowe,et al. The Wavefront Phenomenon of Ischemic Cell Death: 1. Myocardial Infarct Size vs Duration of Coronary Occlusion in Dogs , 1977, Circulation.